TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02644148

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Roux-en-Y Gastrojejunostomy
Description: Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y Gastrojejunostomy
Description: Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
Study: NCT00442676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Capsule, 200 mg/day until 32 weeks of gestation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules of lactose
Study: NCT01879319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab AMD
Description: Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab AI/pen
Description: Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
Study: NCT01722812

Intervention type: DRUG
Group type: OTHER
Intervention: Cromoglicate
Description: Twice daily topical treatment for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Twice daily topical treatment for 14 days
Study: NCT01933256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP2B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP2B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03516409

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biokult
Description: Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~* Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~* DHA + EPA: \>1mg per sachet~* Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets.
Study: NCT02067416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracycline based chemotherapy
Description: standard of care neoadjuvant treatment with anthracycline based chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxane-based chemotherapy
Description: neoadjuvant taxane based chemotherapy given as standard of care
Study: NCT04154696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation of a graft after assessment by normothermic perfusion
Description: Liver transplantation of a graft after assessment by normothermic perfusion
Study: NCT00000450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo Tablet
Study: NCT03280069

Intervention type: DEVICE
Intervention: THERMIeyes® 20 RF System
Description: The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
Study: NCT02976727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Vitamin D (Calcipotriol) application
Description: Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
Study: NCT00512278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02976727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cream application
Description: placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAL application
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL application
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Study: NCT02039011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol
Description: Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
Study: NCT01792934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: may be added to both regimens according to standard procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tumor biopsy
Description: at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
Study: NCT02976727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of the fluorescence intensity
Description: After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurements of the fluorescence intensity
Description: After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
Study: NCT01792934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumor biopsy
Description: at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
Study: NCT03886116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
Study: NCT03772652

Intervention type: OTHER
Intervention: Observation
Description: Soft tissue implant measurements
Study: NCT03340857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intelligent electric bicycle (VELIS) sessions
Description: Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
Study: NCT02976727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
Study: NCT04141592

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Already clinically indicated surgical procedures

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Already clinically indicated surgical procedures
Study: NCT01313832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (RIPC)
Description: RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
Study: NCT02039011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and tiotropium
Description: Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
Study: NCT01760577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (Allergan, Inc, Irvine CA)
Description: patients received intraarticular injections by the same experienced physician using aseptic procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyalgan (Hyalgan, Fidia , Italy)
Description: The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
Study: NCT02514343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 1ml of 10% magnesium sulfate with 1.5 ml of sterile water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 1ml of 10% magnesium sulfate with 1.5 ml of sterile water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
Study: NCT02035514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow autologous mesenchymal stem cells transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow autologous mesenchymal stem cells transplantation
Study: NCT02443701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Warmup program, maximum isometric strengthening, and jump training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Warmup program, maximum isometric strengthening, and jump training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Warmup program, maximum isometric strengthening, and jump training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LASER
Description: a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES
Description: electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
Study: NCT02126163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
Study: NCT01981798

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and occupational therapy
Description: Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
Study: NCT03736148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Manipulation
Description: Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument-assisted Manipulation
Description: The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
Study: NCT06084351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care treatment for hospitalized COVID-19 patients
Study: NCT03240107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levator resection
Description: The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levator tucking
Description: The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene.
Study: NCT02581891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: 3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: 3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
Study: NCT01058733

Intervention type: OTHER
Group type: OTHER
Intervention: Internet
Description: new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
Study: NCT03369366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelActive
Description: NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLS Martin Mandibular Reconstruction Implant
Description: The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
Study: NCT03630146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPeer2Peer program
Description: In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: The control group will receive standard care but without the iPeer2Peer Program.
Study: NCT03842267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin 50mg
Description: * The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin Placebo
Description: * The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* - The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day
Study: NCT03421886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerodentis system
Description: The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invisalign clear aligner system
Description: Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
Study: NCT03679104

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of mucosotomy using endoscopic clips
Description: Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of mucosotomy using OverStitch™ suturing device
Description: Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
Study: NCT00535418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole